TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ondine Biomedical, Inc. ( (GB:OBI) ) has provided an update.
Ondine Biomedical Inc. announced that The Mater Hospital in North Sydney has adopted its Steriwave nasal photodisinfection technology to combat antimicrobial resistance (AMR) in cancer care. This move addresses the heightened risk of drug-resistant infections among cancer patients, particularly those undergoing treatments like chemotherapy and surgery. Steriwave offers a non-invasive, cost-effective solution that reduces infection rates and supports uninterrupted cancer therapies, highlighting its potential to improve patient outcomes and ease healthcare burdens.
The most recent analyst rating on (GB:OBI) stock is a Buy with a £55.00 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.
More about Ondine Biomedical, Inc.
Ondine Biomedical Inc. is a Canadian life sciences company specializing in light-activated antimicrobial therapies, known as photodisinfection, for infection prevention and treatment. The company has a range of investigational products based on its proprietary technology, with applications including nasal decolonization, chronic sinusitis, and ventilator-associated pneumonia. Ondine’s products are approved in several countries and are undergoing clinical trials for regulatory approval in the US.
Average Trading Volume: 367,316
Technical Sentiment Signal: Buy
Current Market Cap: £77.76M
For detailed information about OBI stock, go to TipRanks’ Stock Analysis page.